The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwCLL 2023 | The current SoC in Richter’s transformation and the potential role of CAR T-cell therapy
In this interview, Romain Guieze, MD, PhD, CHU Clermont Ferrand, Clermont Ferrand, France, outlines the current standard of care (SoC) for treating Richter’s transformation (RT), which is treated in the same manner as de novo diffuse large B-Cell lymphoma (DLBCL). As anti-CD19 CAR T-cell therapy has been transformative in treatment of DLBCL, Dr Guieze and his team have investigated the use of this therapy for the treatment of RT in order to elucidate how patient outcomes compare to the SoC. This interview was recorded at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2023 meeting, held in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
